Achieve Life Sciences received an FDA Complete Response Letter for cytisinicline citing manufacturing and labeling issues. It plans to resubmit in the fourth quarter of 2026 and anticipates potential approval by the end of the second quarter of 2027.
QUIT · Achieve Life Sciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 64%
- Last earnings
- Aug 11, 2026
- Latest filing
- 10-Q · Nov 10
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million.
Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer effective as of October 5, 2026, while Mark Oki stepped down from the same role effective as of October 5, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $201.5M | as of September 30, 2026 | — |
| Quit rate (four-week continuous abstinence), Weeks 49–52 | 31.2% | Weeks 49–52 of ORCA-OL trial | — |
| Quit rate (four-week continuous abstinence), Weeks 9–12 | 25.5% | Weeks 9–12 of ORCA-OL trial | — |
| Quit rate among participants new to cytisinicline at end of treatment | 39.4% | End of treatment, ORCA-OL trial | — |
| Quit rate among participants who had taken cytisinicline in a prior trial at end of treatment | 27.8% | End of treatment, ORCA-OL trial | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QUIT
this stock
Achieve Life Sciences, Inc.
|
$645.90M | +18.1% | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 89.0%
- Net QoQ
- +15.4M sh
- Top holder
- Frazier Life Sciences Man…
- Filed
- Nov 10, 2026
- This year
- 19
AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QUIT | -6.7% | -9.7% | +10.8% | -14.1% | +18.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -1.2% | -3.4% | +16.4% | -8.8% | +13.1% |